» Go to news main

Intra‑individual comparison of 18F‑sodium fluoride PET–CT and 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC‑A1): a multicentre, phase 3 trial

Posted by Angie Kinsman on December 1, 2022 in Nuclear Medicine

Congratulations to Dr. Steven Burrell on his latest published article!

Intra-individual comparison of 18F-sodium fluoride PET–CT and 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial

François Bénard, Sara Harsini, Don Wilson, Katherine Zukotynski, Gad Abikhzer, Eric Turcotte, Mariève Cossette, Ur Metser, Jonathan Romsa, Montgomery Martin, Colin Mar, Fred Saad, Jean-Paul Soucy, Bernhard J Eigl, Peter Black, Andra Krauze, Steven Burrell, Alan Nichol, Jean-Claude Tardif

The Lancet Oncology Volume 23, Issue 12, December 2022, Pages 1499-1507

"Summary

Background

Detection of skeletal metastases in patients with prostate cancer or breast cancer remains a major clinical challenge. We aimed to compare the diagnostic performance of 99mTc-methylene diphosphonate (99mTc-MDP) single-photon emission CT (SPECT) and 18F-sodium fluoride (18F-NaF) PET–CT for the detection of osseous metastases in patients with high-risk prostate or breast cancer.

[Read more]"